Annette K Larsen

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Christophe Tournigand, Franck Bonnetain, Olivier Dupuis, 2016, Cancer medicine.

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.

A. Larsen, Annette K Larsen, Djamila Ouaret, 2011, Pharmacology & therapeutics.

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor Angiogenesis

Olivier Poch, Wolfgang Raffelsberger, Eric Guérin, 2012, Molecular medicine.

Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery

Jérôme Alexandre Denis, F. Coulet, A. Larsen, 2016, Molecular oncology.

Dual Inhibition of PI3K/Akt Signaling and the DNA Damage Checkpoint in p53-Deficient Cells with Strong Survival Signaling: Implications for Cancer Therapy

A. Larsen, A. Składanowski, Annette K Larsen, 2007, Cell cycle.

Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation.

Alexander Lorz, Jean Clairambault, Tommaso Lorenzi, 2015, Cancer research.